Helix Biopharma Corp. Appoints Gabrielle M Siegers as the Head of Research & Development

(Toronto, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company that is developing unique therapies in the field of immuno-oncology based on its proprietary technology platform DOS47, is pleased to announce the appointment of Dr. Gabrielle M Siegers, MA, Ph.D., as the Head of R&D based out of the Company’s lab in Edmonton.


Helix – Gabrielle Siegers Apptt – Sep 1 2022